FDA Approves Corcept’s Lifyorli for Platinum-Resistant Ovarian Cancer — Corcept Therapeutics Incorporated

Event summary

FDA approved Corcept’s Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer.
Approval based on ROSELLA trial showing 35% reduction in death risk and 4.1-month median overall survival improvement.
Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist.
Corcept has submitted a Marketing Authorisation Application to the EMA for relacorilant in the EU.
ROSELLA trial enrolled 381 patients across multiple international sites.

The big picture

Corcept’s FDA approval positions Lifyorli as a potential new standard-of-care for platinum-resistant ovarian cancer, a disease with limited treatment options. The approval validates Corcept’s cortisol modulation approach in oncology, opening doors for relacorilant’s development in other cancer types. The strategic significance lies in Corcept’s ability to leverage this success to expand its oncology pipeline and potentially enter new markets.

What we're watching

Market Adoption: How quickly Lifyorli gains market share in the platinum-resistant ovarian cancer space.
Regulatory Progress: Whether the EMA approval process for relacorilant will follow a similar timeline to the FDA.
Pipeline Expansion: The pace at which Corcept advances relacorilant in other cancer indications.